Rochester, NY 7/9/2009 11:18:31 PM
Stock Exchange News - HEB - HEB Shares Details On 2009 Annual Stockholder Meeting - Sourced WhisperFromWallStreet.com
HEMISPHERX BIOPHARMA
Stock Exchange News - HEB - HEB Shares Details On 2009 Annual Stockholder Meeting - Sourced WhisperFromWallStreet.com
COMPANY - HEMISPHERX BIOPHARMA,HEB
NEWS - Hemispherx Biopharma announced that it held its 2009 Annual Meeting of Stockholders. Final voting results will be included in an 8-K to be filed later today. As with last year's Annual Meeting of Stockholders, there was an extremely low turnout. The Company believes that this was due to the fact that more than 40% of its outstanding shares are held outside the United States. Most of these shares are held at European banks that do not participate in the proxies of American companies. Even with the quorum lowered to 40% for the meeting, only approximately 40.34% of the outstanding shares entitled to vote were represented in person or by proxy. At the meeting, each of the five nominees for director named in the Company's proxy statement was elected to a one-year term, the selection of McGladrey & Pullen, LLP as independent auditors for the fiscal year ending December 31, 2009 was ratified and the adoption of the Company's 2009 Equity Incentive Plan was approved.
Real-Time: 2.10 0.10 (5.00%) 11:42am ET
Last Trade: 2.09
Day's Range: 2.03 - 2.25
52wk Range: 0.25 - 4.54
Volume: 1,356,965
ABOUT - Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of new drug therapies for the treatment of viral and immune based chronic disorders. The company?s products include Alferon N Injection for the treatment of genital warts; and Ampligen, an experimental drug that is in human clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, HIV, renal cell carcinoma, and malignant melanoma. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of viral diseases and disorders of the immune system.
---
WhisperFromWallStreet is a news letter focusing on sending specific alerts to our subscribers. These alerts represent which stocks we believe are going to run. Additionally we spend time teaching how to become a better trader. If you like more information or to Sign Up for free alerts, visit us at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT INFORMATION: Nothing in this press release should be interpreted as a solicitation to buy any stock or security represented herein. WhisperfromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers. Information presented here is based on our opinion only.
